Activity Overview
For patients with metastatic triple-negative breast cancer (mTNBC) who are ineligible for frontline immunotherapy-containing regimens, treatment options have been limited to conventional cytotoxic regimens, with antibody-drug conjugates (ADCs) reserved for second- and later lines of therapy. However, recent results from pivotal clinical trials have challenged this paradigm, demonstrating progression-free and even overall survival benefits for the use of TROP2-directed ADCs in the frontline setting.
This podcast features a discussion of the pivotal frontline trial data with these agents and the clinical implications, led by Rohit Gosain, MD and Rahul Gosain, MD.
Target Audience
This educational activity is directed by medical oncologists, nurse practitioners, physician assistants, oncology nurses and other HCPs who manage patients with breast cancer.
Learning Objectives
Upon successful completion of this activity, you should be better prepared to:
- Evaluate recent data from pivotal clinical trials investigating new frontline treatments for mTNBC
- Apply emerging evidence, PD-L1 status, and patient preferences to select optimal first-line therapy for patients with mTNBC
- Identify key adverse events and supportive care strategies associated with new treatment approaches for mTNBC
Rahul Gosain, MD, MBA
Medical Director of Wilmot Cancer Institute at
Webster
Director of Wilmot Cancer Institute Regional
Infusion Services
Assistant Professor of Clinical Medicine
Wilmot Cancer Institute‒University of
Rochester
Rochester, NY
Disclosures: Consultancy/Advisory: AstraZeneca, Gilead, Janssen Oncology; Honorarium: Cor2ed, Integrity CE, Oncology News Central, SignifyMD
Rohit Gosain, MD
Director of Roswell Park Care Network
Southtowns
Assistant Professor of Clinical Medicine
Roswell Park Comprehensive Cancer
Center‒University at Buffalo
Rochester, NY
Disclosures: Consultancy/Advisory: Eisai; Honorarium: Cor2ed, Integrity CE, Oncology News Central, SignifyMD
Adam Brufsky, MD, PhD
Professor of Medicine
Co-Director, Cancer Therapeutics Program
UPMC Hillman Cancer Center
University of Pittsburgh
Pittsburgh, PA
Disclosures: Advisor, Consultant, Fee for Service Recipient: Agendia, AstraZeneca, Bria-Cell, Celcuity, Daiichi Sankyo, Genentech/Roche, Gilead, Lilly, Merck, Myriad, Novartis, Pfizer, Puma, Sanofi; Ownership interests in privately held companies: Celcuity
The staff of Physicians’ Education Resource®, LLC have no relevant financial relationships with ineligible companies.
PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.
Off-Label Disclosure and Disclaimer
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.
GET STARTED WITH THIS PROGRAM:
Register now to gain access to this program.
Create AccountAlready Registered? Login Here
